| abstract |
A composition for treating herpes simplex viral infections in humans is disclosed, comprising about 102 to 108 I.U. of human interferon, about 0.1% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, the composition comprises about 104 to 106 I.U. of human leukocyte interferon, about 1% to 5% by weight of a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carrier. A method for treating herpes simplex viral infections in humans is also disclosed, comprising topically administering an effective amount of said antiherpetic composition to the affected area. Most preferably, an effective amount of said antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication. |